Overview

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Status:
Completed
Trial end date:
2020-05-07
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Sitagliptin Phosphate